Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease (Q38878922)

7 September 2017

1 reference

title

Aβ-Degrading Proteases: Therapeutic Potential in Alzheimer Disease (English)

1 reference

7 September 2017

0 references

Malcolm A Leissring

1

1 reference

7 September 2017

27 June 2016

1 reference

7 September 2017

1 reference

7 September 2017

30

1 reference

7 September 2017

8

1 reference

7 September 2017

667-675

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-016-0364-1

7 September 2017

0 references

cites work

Neuroscience: Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

2015 Alzheimer's disease facts and figures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Contribution of Alzheimer disease to mortality in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Therapeutic strategies for Alzheimer's disease in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

The genetics of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Amyloid-beta isoform metabolism quantitation by stable isotope-labeled kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

The secretases: enzymes with therapeutic potential in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Presenilin: running with scissors in the membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

BACE1 structure and function in health and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Targeting the β secretase BACE1 for Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Skeletal and CNS defects in Presenilin-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Presenilin, Notch, and the genesis and treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

γ-secretase substrates and their implications for drug development in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Lessons from a failed γ-secretase Alzheimer trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Cognitive and Functional Decline in Patients With Mild Alzheimer Dementia With or Without Comorbid Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

An atomic structure of human γ-secretase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Inhibition and modulation of gamma-secretase for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Immunotherapy for Alzheimer disease: the challenge of adverse effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Clearance systems in the brain-implications for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Proteolytic degradation of amyloid β-protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Regulation of distinct pools of amyloid β-protein by multiple cellular proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Intracellular amyloid-beta in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Aβ degradation-the inside story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Expression of BRI-amyloid beta peptide fusion proteins: a novel method for specific high-level expression of amyloid beta peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Abeta40 inhibits amyloid deposition in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Normal cognition in transgenic BRI2-Aβ mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

The AbetaCs of Abeta-cleaving proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Circulating neprilysin clears brain amyloid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Enhanced proteolytic clearance of plasma Aβ by peripherally administered neprilysin does not result in reduced levels of brain Aβ in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Optimization of peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Convection-enhanced delivery of neprilysin: a novel amyloid-β-degrading therapeutic strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Targeted delivery of proteins across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Cerebrovascular smooth muscle cell surface fibrillar A beta. Alteration of the proteolytic environment in the cerebral vessel wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

A novel glucokinase activator modulates pancreatic islet and hepatocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Substance P induced preprotachykinin-a mRNA, neutral endopeptidase mRNA and substance P in cultured normal fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Abeta 42-induced increase in neprilysin is associated with prevention of amyloid plaque formation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a {beta}-secretase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Presenilin-dependent transcriptional control of the Abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Estrogen regulates neprilysin activity in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Enhancement of neutral endopeptidase activity in SK-N-SH cells by green tea extract

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-016-0364-1

Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27349988

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27349988

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Neprilysin gene transfer reduces human amyloid pathology in transgenic mice.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27349988

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40263-016-0364-1

1 reference

7 September 2017

1 reference

PubMed ID

27349988